288 related articles for article (PubMed ID: 17503348)
41. Design of a MUC1-based cancer vaccine.
Hanisch FG
Biochem Soc Trans; 2005 Aug; 33(Pt 4):705-8. PubMed ID: 16042579
[TBL] [Abstract][Full Text] [Related]
42. Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T-cell migration.
Correa I; Plunkett T; Vlad A; Mungul A; Candelora-Kettel J; Burchell JM; Taylor-Papadimitriou J; Finn OJ
Immunology; 2003 Jan; 108(1):32-41. PubMed ID: 12519300
[TBL] [Abstract][Full Text] [Related]
43. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers.
Zhang S; Zhang HS; Reuter VE; Slovin SF; Scher HI; Livingston PO
Clin Cancer Res; 1998 Feb; 4(2):295-302. PubMed ID: 9516914
[TBL] [Abstract][Full Text] [Related]
44. MUC1 in Cancer Immunotherapy - New Hope or Phantom Menace?
Syrkina MS; Rubtsov MA
Biochemistry (Mosc); 2019 Jul; 84(7):773-781. PubMed ID: 31509728
[TBL] [Abstract][Full Text] [Related]
45. A review on development of MUC1-based cancer vaccine.
Gao T; Cen Q; Lei H
Biomed Pharmacother; 2020 Dec; 132():110888. PubMed ID: 33113416
[TBL] [Abstract][Full Text] [Related]
46. Differential glycosylation of MUC1 in tumors and transfected epithelial and lymphoblastoid cell lines.
Poland PA; Kinlough CL; Rokaw MD; Magarian-Blander J; Finn OJ; Hughey RP
Glycoconj J; 1997 Jan; 14(1):89-96. PubMed ID: 9076518
[TBL] [Abstract][Full Text] [Related]
47. Breast cancer immunotherapy: current status and future prospects.
Apostolopoulos V; McKenzie IF; Pietersz GA
Immunol Cell Biol; 1996 Oct; 74(5):457-64. PubMed ID: 8912009
[TBL] [Abstract][Full Text] [Related]
48. Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma.
Henderikx P; Kandilogiannaki M; Petrarca C; von Mensdorff-Pouilly S; Hilgers JH; Krambovitis E; Arends JW; Hoogenboom HR
Cancer Res; 1998 Oct; 58(19):4324-32. PubMed ID: 9766660
[TBL] [Abstract][Full Text] [Related]
49. MUC1-mediated motility in breast cancer: a review highlighting the role of the MUC1/ICAM-1/Src signaling triad.
Haddon L; Hugh J
Clin Exp Metastasis; 2015 Apr; 32(4):393-403. PubMed ID: 25759211
[TBL] [Abstract][Full Text] [Related]
50. MUC1 is a promising therapeutic target for prostate cancer therapy.
Li Y; Cozzi PJ
Curr Cancer Drug Targets; 2007 May; 7(3):259-71. PubMed ID: 17504123
[TBL] [Abstract][Full Text] [Related]
51. Epitope mapping of antigenic MUC1 peptides to breast cancer antibody fragment B27.29: a heteronuclear NMR study.
Grinstead JS; Schuman JT; Campbell AP
Biochemistry; 2003 Dec; 42(48):14293-305. PubMed ID: 14640698
[TBL] [Abstract][Full Text] [Related]
52. Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21.
Adluri S; Gilewski T; Zhang S; Ramnath V; Ragupathi G; Livingston P
Br J Cancer; 1999 Apr; 79(11-12):1806-12. PubMed ID: 10206297
[TBL] [Abstract][Full Text] [Related]
53. The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy.
Agrawal B; Gendler SJ; Longenecker BM
Mol Med Today; 1998 Sep; 4(9):397-403. PubMed ID: 9791863
[TBL] [Abstract][Full Text] [Related]
54. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin.
von Mensdorff-Pouilly S; Verstraeten AA; Kenemans P; Snijdewint FG; Kok A; Van Kamp GJ; Paul MA; Van Diest PJ; Meijer S; Hilgers J
J Clin Oncol; 2000 Feb; 18(3):574-83. PubMed ID: 10653872
[TBL] [Abstract][Full Text] [Related]
55. Molecular evolution of specific human antibody against MUC1 mucin results in improved recognition of the antigen on tumor cells.
Persson J; Bäckström M; Johansson H; Jirström K; Hansson GC; Ohlin M
Tumour Biol; 2009; 30(4):221-31. PubMed ID: 19776674
[TBL] [Abstract][Full Text] [Related]
56. Expression of aberrantly glycosylated tumor mucin-1 on human DC after transduction with a fiber-modified adenoviral vector.
van Leeuwen EB; Cloosen S; Senden-Gijsbers BL; Agervig Tarp M; Mandel U; Clausen H; Havenga MJ; Duffour MT; García-Vallejo JJ; Germeraad WT; Bos GM
Cytotherapy; 2006; 8(1):24-35. PubMed ID: 16627342
[TBL] [Abstract][Full Text] [Related]
57. Indomethacin enhances anti-tumor efficacy of a MUC1 peptide vaccine against breast cancer in MUC1 transgenic mice.
Curry JM; Besmer DM; Erick TK; Steuerwald N; Das Roy L; Grover P; Rao S; Nath S; Ferrier JW; Reid RW; Mukherjee P
PLoS One; 2019; 14(11):e0224309. PubMed ID: 31693710
[TBL] [Abstract][Full Text] [Related]
58. ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors.
Kovjazin R; Volovitz I; Kundel Y; Rosenbaum E; Medalia G; Horn G; Smorodinsky NI; Brenner B; Carmon L
Vaccine; 2011 Jun; 29(29-30):4676-86. PubMed ID: 21570434
[TBL] [Abstract][Full Text] [Related]
59. Advances in MUC1-Mediated Breast Cancer Immunotherapy.
Li Z; Yang D; Guo T; Lin M
Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883508
[TBL] [Abstract][Full Text] [Related]
60. Development and preclinical evaluation of a Bacillus Calmette-Guérin-MUC1-based novel breast cancer vaccine.
Chung MA; Luo Y; O'Donnell M; Rodriguez C; Heber W; Sharma S; Chang HR
Cancer Res; 2003 Mar; 63(6):1280-7. PubMed ID: 12649188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
